Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:3:11-6.
doi: 10.2147/ceg.s6355. Epub 2010 Jan 20.

An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease

Sony Mathews  1 , Ashley Reid, Chenlu Tian, Qiang Cai
Affiliations

An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease

Sony Mathews et al. Clin Exp Gastroenterol. 2010.

Abstract

Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. Proton pump inhibitors (PPIs) are the most effective medication for both initial treatment and maintenance therapy of GERD. Pantoprazole, a first-generation PPI, was approved by the FDA in 2000 for the treatment of erosive esophagitis associated with GERD. It has been used in more than 100 different countries worldwide. It is one of the few PPIs available in multiple forms: a delayed-release oral capsule, oral suspension, and intravenous. Pantoprazole been shown to improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality of life more effectively than histamine-2 receptor antagonists. Evaluated in over 100 clinical trials, pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low incidence of drug interactions. It has also been shown to be safe and effective in special patient populations, such as the elderly and those with renal or moderate liver disease.

Keywords: GERD; esophagitis; pantoprazole.

PubMed Disclaimer

References

    1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;1943;101:1900–1920. quiz. - PubMed
    1. Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag. 2007;3:231–243. - PMC - PubMed
    1. Hollenz M, Stolte M, Labenz J. Prevalence of gastro-oesophageal reflux disease in general practice. Dtsch Med Wochenschr. 2002;127:1007–1012. - PubMed
    1. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998;104:252–258. - PubMed
    1. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST) Scand J Gastroenterol Suppl. 1999;231:48–54. - PubMed